Blog
Monte Rosa inks $5.7B deal with Novartis for immune disease drug development
Monte Rosa Therapeutics has inked a second deal with pharma giant Novartis — and this one is worth up to $5.7 billon.
Monte Rosa Therapeutics has inked a second deal with pharma giant Novartis — and this one is worth up to $5.7 billon.